01:55 PM EST, 12/17/2025 (MT Newswires) -- Vistagen Therapeutics ( VTGN ) said Wednesday a phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder failed to demonstrate a statistically significant improvement on the primary endpoint.

Shares sank 80% following an increase in intraday trading volume to over 61.2 million from a daily average of about 715,000.

Kyverna Therapeutics ( KYTX ) said Wednesday it priced an underwritten public offering of 13.3 million common shares at $7.50 apiece, targeting gross proceeds of about $100 million.

Shares slumped 32% as intraday trading volume soared to over 11.7 million from a daily average of about 1.04 million.

Goldman Sachs downgraded the shares of ARM Holdings ( ARM ) to sell from neutral while adjusting its price target to $120 from $160.

Shares dropped 6.8% as intraday trading volume climbed to about 4.8 million from a daily average of roughly 4.73 million.

Price: 0.87, Change: -3.49, Percent Change: -80.05